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The type III secretion system (T3SS) is employed by a number of Gram-negative bacterial pathogens to inject
toxins into eukaryotic cells. The biogenesis of this complex machinery requires the regulated interaction
between over 20 cytosolic, periplasmic, and membrane-imbedded proteins, many of which undergo
processes such as polymerization, partner recognition, and partial unfolding. Elements of this intricate
macromolecular system have been characterized through electron microscopy, crystallography, and NMR
techniques, allowing for an initial understanding of the spatiotemporal regulation of T3SS-related events.
Here, we report recent advances in the structural characterization of T3SS proteins from a number of
bacteria, and provide an overview of recently identified small molecule T3SS inhibitors that could potentially
be explored for novel antibacterial development.Introduction
Type III secretion systems (T3SSs) are widespreadmacromolec-
ular nanomachines that allow a number of human, plant, and
animal pathogens to inject toxins directly into the cytoplasm of
eukaryotic cells. Although toxin effects can be distinct, ranging
from establishment of symbiosis to pathogenic effects such as
cytoskeletal rearrangement, membrane disruption, and initiation
of apoptosis, the T3SS apparatus itself has been shown to
display notable similarities within different bacterial species
(Cornelis, 2006; Gala´n, 2009). T3SSs are composed of three
main ‘‘parts’’: the basal body, a multi-ring system that spans
both bacterial membranes; a hollow needle-like structure
through which toxins have been proposed to travel in semi-
unfolded form (these two systems together are often globally
referred to as the ‘‘needle complex’’); and the translocon,
a pore inserted into the target eukaryotic membrane formed by
two T3SS hydrophobic proteins that associate with the needle
through a hydrophilic ‘‘bridging’’ partner, the latter of which plays
an important role in immune system modulation (Blocker et al.,
2008; Gendrin et al., 2010; Matteı¨ et al., 2011; Mueller et al.,
2008). The basal body itself is intimately associated with
a number of cytoplasmic and membrane proteins (the ‘‘export
apparatus’’) (Figure 1), which renders the base secretion compe-
tent (Diepold et al., 2010; Wagner et al., 2010). Thus, the T3SS
assemblies involve over 20 different proteins (Marlovits and
Stebbins, 2010; Moraes et al., 2008; Mueller et al., 2008; Worrall
et al., 2011), and are genetically and structurally related to the
bacterial flagellum (Blocker et al., 2003). In addition many
proteins involved in T3SS biogenesis are produced in the bacte-
rial cytoplasm in complex with cognate chaperones, adding to
the arsenal of molecules whose expression, secretion, and/or
translocation must be under tight regulatory control. Notably,
despite the overall similarity of T3SSs among different bacterial
species, genes that code for individual components often do
not follow the same organizational profile within T3SS-encodingStruoperons, with the most notable distinctions being identified for
genes involved in the regulatory cascade and for the basal
body itself (Figure 2).
Studies of the individual steps involved in T3SS biogenesis, as
well as of the locations of different proteins within the assembled
systems and potential conformational changes required for
T3SS activation, have been hampered by a number of factors.
In addition to the sheer complexity of the system, the membra-
nous or fibrous character of a number of the proteins involved
in forming the T3SS and the relatively low resolutions of electron
microscopy maps used for protein localization have in the past
often led to conflicting results. However, recently, elegant
cryomicroscopy studies of purified needle complexes, crystal
structures of the soluble domains of proteins involved in basal
body formation or host cell interaction, and NMR and FTIR
analyses of needle proteins have greatly advanced our structural
knowledge of the T3SS. In addition high-resolution crystal struc-
tures of all classes of T3SS chaperones are now available, allow-
ing for more detailed study of the structural requirements for
partner stabilization in the bacterial cytoplasm. This review will
focus on the most recent advances in structural characterization
of many of these components and will explore how this know-
ledge can help in the development of novel antibacterial agents
targeting these multifaceted assemblies.
Detailed Features and Assembly of the Basal Body
Assembly of a secretion- and injection-competent T3SS occurs
in a stepwise fashion and involves three major steps: (1) forma-
tion of the basal body, including outer membrane and inner
membrane rings; (2) assembly of the needle substructure; and
(3) secretion and localization of translocon-forming proteins
onto the target cell membrane (Figure 1; see Movie S1 available
online). The basal body consists of two sets of rings of different
diameters, positioned within both the outer and inner bacterial
membranes (and, thus, will be referred to as OMR and IMR).cture 19, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 603
Figure 1. Schematic Diagram of the T3SS of
Yersinia spp
The basal body is a multi-ring structure that
anchors the system to the two bacterial
membranes. Upon its formation the needle protein
potentially travels through the rings (step 1) and
self-polymerizes on the outside of the bacterium.
Subsequently, translocon proteins (step 2) are
secreted, and finally, toxins/effectors are injected
into the eukaryotic cytoplasm (step 3) (see Movie
S1). The table includes homologous proteins in
Pseudomonas, Shigella, Salmonella, and patho-
genic E. coli spp. n.i., molecules that were not yet
identified.
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systems, the basal body seems to be composed of three distinct
proteins that form oligomers displaying at least 12-fold sym-
metry (although in some systems, higher order has been re-
ported) (Hodgkinson et al., 2009; Schraidt et al., 2010; Spreter
et al., 2009).
The IMR, proposed to be the first ring to be assembled within
the base (Kimbrough and Miller, 2002), is composed of two
proteins (YscJ/MxiJ/PrgK, and YscD/MxiG/PrgH in Yersinia,
Shigella, and Salmonella spp, Figures 1 and 3) that oligomerize
to form two concentric rings of different diameters. Recently,
through a combination of cryo-electron microscopy, single-
particle analysis, and surface-labeling studies, Schraidt et al.
(2010) confirmed that PrgK and PrgH are the main components604 Structure 19, May 11, 2011 ª2011 Elsevier Ltd All rights reservedof the Salmonella IMR. The data indicated
that PrgK forms the smaller, IMR and is
buried within the outer PrgH assembly,
an observation supported by the fact
that the N and C termini of PrgH are
located on different sides of the inner
membrane, with the C terminus facing
the periplasm and, thus, contacting the
secretin InvG (see below) (Schraidt
et al., 2010).
The OMR is formed primarily by
a component of the secretin family.
Secretins,whicharecomposedofaN-ter-
minal periplasmic region and a conserved
membrane-inserted ‘‘secretin homology
region’’ at the C-terminal end, form highly
stable oligomers, typically with 12–14
subunits. Secretin oligomerization
creates central pores large enough to
allow the secretion of unfolded or partially
folded proteins and are often the OMR-
forming structures in bacterial secretion
systems (Chami et al., 2005; Hodgkinson
et al., 2009; Reichow et al., 2010; Schraidt
et al., 2010). In recent reconstructions of
Salmonella and Shigella needle com-
plexes, the secretin protrudes into the
periplasmic space, forming a ‘‘neck’’
region that is potentially formed by its N
terminus and directly contacts the IMR
(Hodgkinson et al., 2009; Schraidt et al.,2010). This observation was confirmed by experiments in
which the crystal structure of the soluble N-terminal domain of
EscC (the E. coli secretin) was docked into the S. typhimurium
T3SS electron density map. This not only showed that this region
can be successfully positioned adjacent to the C-terminal
secretin core but also that it can act as a bridge between the
C-terminal region of the secretin and other periplasmic compo-
nents. Notably, EscC21-174 displays amodular fold with two small
a/b domains separated by a flexible linker (Figure 3), an arrange-
ment that is shared by the periplasmic domains of secretins of
other secretion systems, such as GspD from the T2SS of Vibrio
cholerae (Korotkov et al., 2009), and DotD from the T4bSS of
Legionella pneumophila (Nakano et al., 2010). Importantly, the in-
terdomain linker was shown by mutagenesis to play a key role in
Figure 2. Organization of T3SS Operons in
Different Bacterial Species
Only operons containing transcriptional regula-
tors, basal body, and needle formation genes are
shown. Strains include Yersinia pestis CO29
(NC_003143), P. aeruginosa PAO1 (NC_002516),
S. flexneri 301 (NC_004851), Salmonella enterica
serovar Typhimurium LT2 (NC_003197), and
E. coli (enteropathogenic) O127:H6 E2348/69
(NC_011601). Homologous genes are highlighted
in the same color.
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Reviewsecretion through the T3SS. Thus, it is conceivable that this flex-
ibility allows for structural rearrangements previously observed in
the outer membrane (OM) region and that are essential for T3SS
functionality (Marlovits et al., 2006; Spreter et al., 2009).
Secretin functionality within the OM requires key molecules,
such as pilotins and other lipoproteins, which participate in
membrane recognition, oligomerization, and stabilization of their
cognatesecretinwithin thebilayer (Burghoutetal., 2004;Trindade
et al., 2008; Zenk et al., 2007). Pilotins are relatively small (15 kDa),
essential proteins that display a classic lipoprotein LxGC lipida-
tion motif at their N terminus. To date, the only available pilotin
structure is that of MxiM (Figure 3), which stabilizes MxiD, the
T3SS secretin fromShigella flexneri (Lario et al., 2005).MxiM folds
into a ‘‘cracked b-barrel’’ displaying a 8 A˚ wide, 20 A˚ deep central
groove that binds a negatively charged lipid. Recently, Okon et al.
(2008) solved the structure of MxiM in the presence of the
C-terminal peptide from the secretin MxiD, and showed that,
upon binding, this unstructured region folds into a turn-helix
motif that covers the hydrophobic cavity. This mechanism could
prevent the secretin from being prematurely inserted into the
OM (Okon et al., 2008). The same authors propose that despite
low sequence identities, pilotins from different species or secre-
tion systems could act in a similar fashion.
Assembly of the Inner Membrane Export Apparatus
Subsequent to assembly of thebasal body, this structuremust be
rendered competent for secretion (Kubori et al., 2000; Sukhan
et al., 2001). This function is accomplished by the ‘‘export appa-
ratus,’’ which involves a number of membrane proteins that are
conserved both at the genetic and structural level in a number
of bacterial species (Figures 1–3). In the Salmonella SPI-1
T3SS, the export apparatus is formed by InvA, SpaP, SpaQ,
SpaR, and SpaS. Recently, Wagner et al. (2010) showed that
membrane proteins from the Salmonella export apparatus form
a platform onto which the needle complex can assemble withinStructure 19, May 11, 2011a single holo structure. Interestingly,
Diepold et al. (2010), by studying the
Yersinia Ysc system, also concluded that
such an assembly is required for forma-
tion of the needle complex, although in
this case formation of theOMR (harboring
the secretin) precedes that of the IMR.
These findings suggest that despite their
overall structural similarity, T3SS from
different microorganisms can display
distinct biogenesis pathways.
A number of individual components of
the export apparatus have been theobject of structural studies, and the most recent, exciting work
has concentrated on membrane protein YscU (Yersinia) and
homologs Spa40 (S. flexneri), SpaS (S. typhimurium), and EscU
(E. coli). These proteins possess four transmembrane helices
and a long cytoplasmic C-terminal tail that undergoes autocleav-
age, which was suggested as being a mechanism employed by
the T3SS to switch from the secretion of early to late substrates.
The globular fold of these ‘‘molecular switches’’ consists of
a five-stranded mixed b sheet surrounded by four a helices;
a surface-located type II b-turn harbors the NPTH cleavagemotif
(Figure 3). Cleavage has been proposed to generate a conforma-
tional modification and a subsequent locally modified electro-
static surface that plays a key role in the interaction with other
components of the export apparatus. Mutations that block the
cleavage reaction render the system defective for secretion of
needle subunits (see below) and translocation of pore-forming
proteins, and highlight the potential importance of the conforma-
tional modification in specificity of secreted substrates (Deane
et al., 2008, 2010; Lountos et al., 2009; Sorg et al., 2007; Worrall
et al., 2011; Zarivach et al., 2008).
InvA from S. typhimurium is the largest protein of the export
apparatus for which structural data are available, but its role in
T3SS functionality remains largely unknown. It consists of
a highly conserved 35 kDa N-terminal region predicted to
contain seven transmembrane helices and a 40 kDa cytoplasmic
soluble domain, potentially located within the cytoplasm. The
structure of the latter domain reveals a compact globular fold
harboring four subdomains (SD1–SD4, Figure 3) (Lilic et al.,
2010; Worrall et al., 2010). Of note is the fact that the structure
of the first subdomain (SD1) is highly reminiscent of that of the
peripheral stalk of the archaeal A0A1 ATPases. In light of the
fact that FlhA, the flagellar homolog of InvA, has been shown
to interact with the ATPase FliI (Minamino and Namba, 2008) it
is conceivable that SD1 could potentially interact with the
T3SS ATPase (Worrall et al., 2010). Strikingly, SD2 sharesª2011 Elsevier Ltd All rights reserved 605
Figure 3. Structural Overview of the T3SS Base-Forming Proteins
Top left showsOMR-forming proteins: EscC (Protein DataBank ID code 3GR5) andMxiM (1Y9T). Top right illustrates IMR-forming proteins: PrgH (3GR1) and EscJ
(1YJ7). Bottom shows export apparatus: HrcQb (YscQ-homolog; 1O9Y); EscN (2OBL); EscU (3BZL); YscU (2JLH); SpaS (3CO1); Spa40 (2VT1); and InvA (2X49).
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GspD, and EscC. These molecules have all been proposed to
associate into rings, which leads to the tempting suggestion
that InvA (and its homologs) could itself potentially form ring-
like structures. However, this type of oligomeric association
has not been observed for InvA. Thus, the C-terminal domain
of InvA could function as a mediator of interactions with other
T3SS components or with the membrane itself (Lilic et al.,
2010; Worrall et al., 2010).
T3SSs harbor an essential ATPase (InvC/Spa47/YscN in
Salmonella, Shigella, and Yersinia spp, respectively) that is
among the best-conserved proteins of the export apparatus,
due to the fact that it displays high sequence homology among
different species and is closely related to the flagellar FliI
ATPase (Cornelis, 2006). Although the structure of the ATPase
will not be discussed in the context of this review, it is of interest
that it has been implicated in chaperone/substrate recognition
and subsequent dissociation and unfolding of substrates, in
a process that utilizes ATP hydrolysis to energize effector secre-
tion but also depends on the proton motive force (Akeda and
Gala´n, 2005; Lorenz and Bu¨ttner, 2009; Minamino and Namba,
2008; Zarivach et al., 2007). However, the precise mechanism
of this process remains to be determined, especially in light of
recent findings that report that the InvC ATPase is not necessary
for formation of the chaperone-sorting platform in Salmonella
spp (Lara-Tejero et al., 2011). Inhibition of ATPase activity by
a partner molecule has been reported in the Yersinia system,
where YscL (a homolog of flagellar FliH) interacts with YscN
whether the bacterium is secreting effectors or not. This interac-
tion could be involved in tethering YscN to the export apparatus
itself (Blaylock et al., 2006).
Injectisome Biogenesis: Needle Formation
and Regulation
Once the OMR/IMR and the export apparatus are in place, the
T3SS needle is synthesized (Sukhan et al., 2001). The T3SS nee-606 Structure 19, May 11, 2011 ª2011 Elsevier Ltd All rights reserveddle is formed by a single protein that is synthesized in the cyto-
plasm and polymerized only after secretion to the surface
(Kubori et al., 2000; Marlovits et al., 2004; Quinaud et al.,
2005). Polymerization is ensured by amino acids residing in the
C-terminal region of these highly helical proteins; in fact most
structures of needle proteins in monomeric forms are C-terminal
truncations (Deane et al., 2006; Wang et al., 2007; Zhang et al.,
2006). Thus, within the bacterial cytoplasm, the T3SS needle-
forming protein must be prevented from undergoing self-
assembly or it will be rapidly degraded (Ple´ et al., 2010; Quinaud
et al., 2005). This task is accomplished by sequestering of the
C-terminal residues of T3SS needle proteins by their cognate
chaperones (see below).
Although the mechanism of cytoplasmic stabilization of the
needle protein seems to be well established, that of needle
polymerization has been a matter of fascinating controversy.
Overexpression of needle proteins generates fibers with lengths
>1 mM (Quinaud et al., 2005), potentially following a monodirec-
tional assembly pattern where protomers are added to the tip
(Poyraz et al., 2010). Cordes et al. (2003) docked the crystal
structure of S. flexneri MxiH onto a 17 A˚ electron microscopy
reconstruction of the purified needles, suggesting that poly-
merization occurs through head-to-tail association of MxiH
monomer. However, recently, Poyraz et al. (2010) recorded
time-dependent Fourier transform infrared (FTIR) spectra of
Salmonella PrgI and identified a backbone a helix-to-b strand
conversion that involves approximately 20% of the residues
and occurs concomitantly with needle polymerization. Analysis
of the polymerized PrgI structure by solid-state NMR revealed
that these conformational changes occur within the highly
conserved 18 C-terminal residues of PrgI, which suggests that
such a fiber-formation mechanism could be common to different
species (Poyraz et al., 2010). The commonality of the T3SS fiber-
formation mechanism could be an interesting and tractable
Achilles’ heel that could be exploited toward the development
of novel antibacterials and/or vaccines (see below).
Figure 4. A Gallery of T3SS Chaperones
Class IA and IB chaperones share a common
overall heart-shaped structure, whereas class II
and class III chaperones display TPR-like folds. In
the latter class a smaller partner protein (blue) is
required to stabilize the main chaperone (green).
Depicted molecules in the gallery include SycT
(2BSJ), SycE (1JYA), SicP (1JYO), SycH (1TTW),
SigE (1K3S), SrcA, (3EPU), AvrPphF (1S28), ExsC
(3KXY), Spa15 (1RY9), InvB (2FM8), PcrH (2XCB),
IpgC (4GZ2), SycD (2VGX), PscG-PscE (2UWJ),
and YscG-YscE (2P58).
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Prior to becoming engaged either in formation of the T3SS appa-
ratus or being injected into the target cytoplasm in order to
manipulate host cell function, most T3SS secretion substrates
are present in the bacterial cytoplasm in complex with dedicated
chaperones. These proteins, which sequester substrates in
a secretion-competent state (Stebbins and Gala´n, 2001), have
been organized into three classes, depending on the partner
they recognize. Class I chaperones recognize one (IA) or more
(IB) effector molecules, whereas class II chaperones interact
with translocators, and class III chaperones sequester the nee-
dle-forming proteins, impairing self-polymerization (Cornelis,
2006; Parsot et al., 2003). Although many laboratories have
been working on structure and function of T3SS chaperones
for a number of years, it is only recently, with the solution of
a number of class II structures, that the gallery of chaperone
folds could be completed (Figure 4). All chaperone classes shareStructure 19, May 11, 2011low sequence identities but similar
biochemical features, including a small
size (typically between 110 and 160 resi-
dues) and an acidic pI (Parsot et al.,
2003).
Class I chaperones are the most exten-
sively studied because a large number of
structures have been reported either in
apo or effector-bound form. The two
subclasses of chaperones share the
same overall heart-shaped dimeric struc-
ture, which consists of a twisted b sheet
with two or three lateral a helices. The
major secondary structure element of
the interface is the ‘‘dimerization helix,’’
which runs parallel in class IA molecules
and at an angle in class IB (van Eerde
et al., 2004). It is of interest that the recent
structure of a complex between a short
region of ExsE, an effector involved in
transcriptional activation in P. aerugi-
nosa, and its cognate chaperone ExsC
also reveals that the latter carries a class
IA fold (Vogelaar et al., 2010), even
though ExsE is not a molecule that will
directly affect the target cell but rather
a member of a transcriptional regulation
cascade (Thibault et al., 2009).
Class II and class III chaperones,
although binding to molecules that carrytotally different functions, have remarkably similar structures.
Both classes display tetratricopeptide (TPR) folds composed
of three TPR motifs each (TPR motifs are characterized by two
antiparallel helices). TPR-harboring proteins are widespread in
eukaryotic organisms and are involved in the establishment of
protein-protein contacts (Grove et al., 2008). Class II chaperones
bind to and stabilize the hydrophobic translocon-forming
molecules; intriguingly, the same chaperone recognizes both
the major T3SS translocator (two potential transmembrane
regions) and theminor translocator (one potential TM). The ques-
tion of how a single, small chaperone can bind to two different
molecules of much greater size has been amatter of controversy
(Barta et al., 2010; Bu¨ttner et al., 2008; Job et al., 2010; Lunelli
et al., 2009; Matteı¨ et al., 2011). The structures of class II chap-
erones PcrH (P. aeruginosa) and IpgC (S. flexneri) in complex
with short regions from both translocator homologs reveal that
both 1:1 and 2:1 stoichiometries are possible, with the concaveª2011 Elsevier Ltd All rights reserved 607
Figure 5. TPR Folds Recognize Helical and
Stretched Peptides
(A) A prototypical class III chaperone, PscG (light
blue), is shown in complex with PscE (light brown)
and the C-terminal region of PscF (red). The inter-
action between PscF and PscG is mediated by an
amphipathic helix located within the concave
region of the PscG TPR fold (Quinaud et al., 2007);
hydrophobic residues are shown in green, hydro-
philic in yellow.
(B) PcrH, a class II chaperone, in complex with
a peptide from PopD (yellow), which also occupies
the concave region of the TPR fold of PcrH but in
outstretched form (Job et al., 2010).
(C) Eukaryotic TPR-containing HOP in complex
with a peptide from Hsp90; here, the concave
region of the TPR is also recognized by an out-
stretched peptide (Scheufler et al., 2000). Hsp90
interacts with HOP in an elongated fashion, highly
similar to PcrH:PopD. Structures on the right
are rotated axially by 90 in relation to the ones on
the left.
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partner is bound (Job et al., 2010; Lokareddy et al., 2010; Lunelli
et al., 2009). This interaction region is essential for T3SS func-
tionality becausemutations that affect the hydrophobic contacts
abrogate secretion and, consequently, cytotoxicity of a clinical
Pseudomonas strain (Job et al., 2010).
In Pseudomonas and Yersinia, needle proteins PscF and YscF
are found in the bacterial cytoplasm associated with a complex
between a class III chaperone (PscG and YscG) and a partner
protein (PscE and YscE) (Quinaud et al., 2007; Sun et al.,
2008). The structure of the PscE-PscF55-85-PscG complex
from P. aeruginosa, which includes the full C-terminal region of
PscF but lacks the N-terminal helical hairpin observed in other
monomeric needle protein structures (Deane et al., 2006;
Wang et al., 2007), reveals that the C terminus of PscF folds
into an amphipathic a helix that is stabilized by the concave
region of PscG’s TPR (Figure 5A). Notably, PscF does not
interact with PscE, whose role seems to be the stabilization of
PscG; this is also observed in the YscE/YscF/YscG complex
from Yersinia (Quinaud et al., 2007; Sun et al., 2008). Mutations608 Structure 19, May 11, 2011 ª2011 Elsevier Ltd All rights reservedwithin the PscF-PscG interaction region
abrogate PscF secretion and, thus,
starkly diminish the cytotoxicity potential
of Pseudomonas (Ple´ et al., 2010). It is of
note that BLAST analyses of the three
proteins involved in the ternary complex
described above reveal a limited number
of ‘‘clear hits.’’ Needle proteins with con-
siderable sequence identity (especially in
the C-terminal helix) could be identified
in species including Vibrio parahae-
molyticus, Photorhabdus luminescens,
S. flexneri, and Aeromonas hydrophila
(Quinaud et al., 2007; Tan et al., 2009),
although PscE and PscG homologs could
not be identified in Shigella. This could
potentially suggest slight modifications
in the needle regulation mechanisms in
the latter organism.Although both class II and class III chaperones display TPR
folds, their bound substrates display distinct secondary struc-
ture profiles. PscG/YscG recognize the fiber-forming C termini
of PscF/YscF that form stable amphipathic helices, with the
hydrophobic helical half facing the interior of the TPR’s concave
region and the polar half facing the solvent (Quinaud et al., 2007;
Sun et al., 2008) (Figure 5A). However, class II chaperones
recognize outstretched peptides (Figure 5B) (Job et al., 2010;
Lunelli et al., 2009). It is precisely the latter form of recognition
that emulates the binding mode of eukaryotic TPR-carrying
molecules to their targets, as seen for example in the complex
between adaptor protein HOP (Hsp-organizing protein) and the
outstretched C terminus of Hsp90 (Figure 5C) (Cortajarena
et al., 2010; Kajander et al., 2009; Scheufler et al., 2000).
Because eukaryotic TPRs have been the targets for the develop-
ment of small molecule inhibitors, this common mode of binding
suggests that lessons derived from studies in blocking protein-
protein interactions in eukaryotic TPR systems could be adapted
to TPRs that play key roles in bacterial infection, as is the case of
the T3SS (see below).
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which clearly reveals only two main general folds, brings up yet
another interesting point. Class II and class III chaperones bind
early secretion substrates, such as needle proteins and translo-
cators, whose timely polymerization or oligomerization is neces-
sary for formation of the T3SS itself—these fold into all-helical
TPRs. Class I chaperones, which stabilize late substrates (effec-
tors and toxins that are secreted/injected only after the T3SS
structure is fully formed) are mixed a/b structures. This observa-
tion suggests that the structure of the chaperone itself may
contain an ‘‘early substrate’’/’’late substrate’’ signal (Job et al.,
2010) and plays a key role in the temporal secretion order of
T3SS substrates (Birtalan et al., 2002). The recent report that
chaperones are recognized by a secretion-sorting platform
located at the base of the T3SS (Lara-Tejero et al., 2011) is an
additional indication of the complexity of the role played by
chaperones in the T3SS regulation mechanism.
Small Molecule Inhibitors as Virulence Blockers
In the face of the growing problem of antimicrobial resistance,
identified for almost every class of antibiotic that is presently on
the market, the search for new drug development targets has
been a strategy of choice for a number of laboratories. Traditional
antibiotics target cell wall biosynthesis, protein synthesis, DNA
replication, andRNA transcription, anddue to theessential nature
of these processes for bacterial growth and survival, ligands that
block them impose selective pressure that leads to the eventual
development of resistance. Naturally, an alternative strategy
would be to target processes that are not absolutely required
for bacterial survival, such as the T3SS, but whose inhibition
would stymie infectivity or disrupt the interaction between path-
ogen and host. This approach could potentially decrease the
selective pressure for development of resistance, allowing the
bacterium to be cleared by the immune system with limited
impact on the host (Clatworthy et al., 2007; Keyser et al., 2008).
Most of themolecules identified as being inhibitors of the T3SS
have been done so by chemical screening, which have identified
compounds that broadly inhibit a large number of T3SS-carrying
pathogens. However, up until now, few laboratories have charac-
terized the precisemacromolecular target of the inhibitors identi-
fied; notable exceptions are benzimidazoles, which have been
shown to inhibit the transcription factors LcrF of Y. pseudotuber-
culosis (Garrity-Ryan et al., 2010) and ExsA from P. aeruginosa
(Grier et al., 2010) (Figure 6A). Notably, structurally unrelated
molecules (such as salicylidene acylhydrazides and thiazolidi-
nones, Figures 6B and 6C) have been reported to affect needle
complex formation or assembly in distinct systems, and to block
secretion without affecting cell viability of both extracellular and
intracellular pathogens, including Yersinia, Shigella, Chlamydia,
and Salmonella spp (Aiello et al., 2010; Muschiol et al., 2006;
Negrea et al., 2007; Nordfelth et al., 2005; Veenendaal et al.,
2009; Wolf et al., 2006). Shigella cells treated with salicylidene
acylhydrazides revealed defects in needle assembly that resem-
bled those of mutants with modifications in the T3SS export
apparatus (Veenendaal et al., 2009), whereas S. typhimurium
cells grown in the presence of a thiazolidinone displayed
a decreased amount in needle complex proteins (Felise et al.,
2008). Interestingly, the latter molecule also had an effect on
the T3SS of Yersinia, the T2S system of Pseudomonas, and theStruT4P secretion system of Francisella spp, leading the authors to
suggest that its main macromolecular target could be the
secretin, a common OM element (Felise et al., 2008). Thiazolidi-
nones have also been reported as inhibiting systems not related
to bacterial infection, which suggests that they could represent
multifaceted therapeutic agents (Dayam et al., 2006).
Sulfonyl amino benzanilides (Figure 6D) and salicylidene ani-
lides (Figure 6E) have been shown to affect expression of
T3SS-related genes in enteropathogenic E. coli and block
different pathways leading to secretion of effectors in Yersinia
spp (Gauthier et al., 2005; Kauppi et al., 2003). In addition, cami-
noside A, a glycolipid isolated from a marine sponge (Figure 6F),
was shown to inhibit secretion by enteropathogenic E. coli
(Linington et al., 2002). However, further development of these
initial hits into novel potential antibiotics will require the charac-
terization of their macromolecular targets and considerable
structural efforts leading to small molecule improvement.
An alternative strategy to cell-based screening for inhibitor
identification involves the exploration of possible ligand recogni-
tion sites on the high-resolution structure of a potential target.
The essential nature of T3SS chaperones for infectivity, the avail-
ability of a number of such structures from different pathogens,
and the identification of TPR chaperone-effector interactions
that are essential for maintenance of pathogenesis (Bro¨ms
et al., 2006; Job et al., 2010; Lunelli et al., 2009; Quinaud et al.,
2007) suggest that obstruction of such protein-protein interac-
tions could represent a yet unexplored approach toward T3SS
inhibitor development. Within eukaryotic systems, an example
of the success of this strategy involves Hsp90, a ubiquitous
chaperone that aids in the folding process of a number of onco-
genic proteins and recognizes TPR modules. The Hsp90-TPR
interaction is of interest for the development of novel antineopla-
sia treatments, andmolecules that specifically inhibit the interac-
tion between Hsp90 and the TPR domain of its partner molecule
HOP have been identified and shown to be effective in vivo
(Yi and Regan, 2008). As discussed above, a number of patho-
gens carry T3SS class II chaperones that bind a section of their
cognate substrates as outstretched peptides in a strikingly
similar fashion to the HOP-Hsp90 complex (Scheufler et al.,
2000). This observation suggests that the concave region of
bacterial TPRs could also be targeted by small molecule inhibi-
tors, as is the case for Hsp90-HOP. Initial evidence confirming
this hypothesis is available in the authors’ laboratory; proof
that such molecules could have an effect in vivo will require
further experimentation.
Conclusions
Despite the extraordinary effort made by a number of laborato-
ries in the past few years to structurally and functionally charac-
terize the T3SS, several questions still remain unanswered. One
major point of interest is the nature of the signal that cues the
bacterium into initiating the secretion of T3SS components
upon recognition that a target cell is to be attacked. Another
area where to date little progress has beenmade is the structural
characterization of the translocon, and the mode of its associa-
tion with the T3SS needle. Two of the translocon components
have been shown to fold as molten globules, even in the pres-
ence of their cognate chaperones; subsequent to recognition
of the target lipid interface, they become membrane imbeddedcture 19, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 609
Figure 6. Representative Structures of Small Molecules that Inhibit the T3SS
The right side of the figure describes inhibition effects observed mostly through the employment of cellular-based assays.
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Reviewand oligomerize. The complexity of these events could require
the employment of novel methodologies for their structural char-
acterization, including preparation of samples in lipid nanodiscs
(Katayama et al., 2010), meso (lipidic cubic phases) crystalliza-
tion (Johansson et al., 2009), or a combination of cryo-electron
tomography and 3D image averaging (Bartesaghi and Subrama-
niam, 2009). In addition, given the interest in exploring the T3SS
as a target for antimicrobial development, it seems likely that the
system will continue to be the object of significant structural and
functional efforts.SUPPLEMENTAL INFORMATION
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